TWICE DAILY N-ACETYLCYSTEINE 600 MG FOR EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PANTHEON): A RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

Background. Increased oxidative stress and inflammation has a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti-inflammatory properties, such as N-acetylcysteine, might provide a useful therapeutic approach for COPD. We aimed to assess whether N-acetylcysteine could reduce the rate of exacerbations in patients with COPD.

Methods. In our prospective, randomised, double-blind, placebo-controlled, parallel-group study, we enrolled patients aged 40–80 years with moderateto-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) / forcedvital capacity < 0.7 and FEV1 of 30–70 % of predicted) at 34 hospitals in China. We stratified patients according to use of inhaled corticosteroids (regular use or not) at baseline and randomly allocated them to receive N-acetylcysteine (one 600 mg tablet, twice daily) or matched placebo for 1 year. The primary endpoint was the annual exacerbation rate in patients who received at least one dose of study drug and had at least one assessment visit after randomisation. This study is registered with the Chinese Clinical Trials Registry, ChiCTR-TRC-09000460.

Findings. Between June 25, 2009, and Dec 29, 2010, we screened 1 297 patients, of whom 1 006 were eligible for randomisation (504 to N-acetylcysteine and 502 to placebo). After 1 year, we noted 497 acute exacerbations in 482 patients in the N-acetylcysteine group who received at least one dose and had at least one assessment visit (1.16 exacerbations per patient-year) and 641 acute exacerbations in 482 patients in the placebo group (1.49 exacerbations per patient-year; risk ratio 0.78, 95% CI 0.67–0.90; p = 0.0011). N-acetylcysteine was well tolerated: 146 (29 %) of 495 patients who received at least one dose of N-acetylcysteine had adverse events (48 serious), as did 130 (26 %) of 495 patients who received at least one dose of placebo (46 serious). The most common serious adverse event was acute exacerbation of COPD, occurring in 32 (6 %) of 495 patients in the N-acetylcysteine group and 36 (7 %) of 495 patients in the placebo group.

Interpretation. Our findings show that in Chinese patients with moderate-to-severe COPD, long-term use of N-acetylcysteine 600 mg twice daily can prevent exacerbations, especially in disease of moderate severity. Future studies are needed to explore efficacy in patients with mild COPD (GOLD I).

1. Vestbo J., Hurd S.S., Agusti A.G. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347–365.

2. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.

3. Spencer S., Calverley P.M., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J. 2004; 23: 698–702.

4. Wouters E.F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.

5. Blackwell T.S., Blackwell T.R., Holden E.P. et al. In vivo antioxidant treatment suppresses nuclear factor–kappa B activation and neutrophilic lung infl ammation. J. Immunol. 1996; 157: 1630–1637.

6. van Overveld F.J., Demkow U., Gorecka D. et al. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J. Physiol. Pharmacol. 2005; 56 (Suppl. 4): 135–142.

7. Dekhuijzen P.N.R. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 23: 629–636.

8. Ueno T., Yamada M., Igarashi Y., Ogawa T. N-acetyl cysteine protects osteoblastic function from oxidative stress. J. Biomed. Mater. Res. A. 2011; 99: 523–531.

9. Sadowska A.M., Manuel-Y-Keenoy B., De Backer W.A. Antioxidant and anti-infl ammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo doseeffects: a review. Pulm. Pharmacol. Ther. 2007; 20: 9–22.

10. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebocontrolled clinical trials. Clin. Ther. 2000; 22: 209–221.

11. Gerrits C.M., Herings R.M., Leufkens H.G., Lammers J.W. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 795–798.

12. Decramer M., Rutten-van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on N-acetylcysteine Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005; 365: 1552–1560.

13. Schermer T., Chavannes N., Dekhuijzen R. et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103: 542–551.

14. Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Investig. 2005; 25: 401–408.

15. Zheng J.P., Wen F.Q., Bai C.X. et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD. 2013; 10: 164–171.

16. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

17. Burge S., Wedzicha J.A. COPD exacerbations: defi nitions and classifi cations. Eur. Respir. J. 2003; 21 (Suppl. 41): 46–53.

18. Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371: 2013–2018.

19. Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

20. Tashkin D.P., Celli B., Senn S. et al, for the UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554. 21. Zhou Y., Wang X., Zeng X. et al. Positive benefi ts of theophylline in a randomised, double-blind, parallel-group, placebo controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006; 11: 603–610.

21. Tse H.N., Raiteri L., Wong K.Y. et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, doubleblind, randomised, placebo-controlled HIACE study. Chest. 2013; 144: 106–118.

22. Jenkins C.R., Jones P.W., Calverley P.M. et al. Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.

23. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecifi ed subgroup analysis of a randomized controlled trial. Lancet. 2009; 374: 1171–1178.

24. Zheng J.P., Zhong N.S., Jiang M., Zeng G.Q. Carbocisteine for acute exacerbations of COPD-authors' reply. Lancet. 2008; 372: 1631–1632.

25. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

26. Zheng J.P., Yang L., Wu Y.M. et al. The efficacy and safety of combination salmeterol (50 μg)/fl uticasone propionate (500 μg) inhalation twice daily via Accuhaler in Chinese patients with COPD. Chest. 2007; 132: 1756–1763.

27. Zhong N., Wang C., Yao W. et al. Prevalence of chronic obstructive pulmonary disease in China: a large populationbased survey. Am. J. Respir. Crit. Care Med. 2007; 176: 753–760.

28. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361: 449–456.

29. Thomsen M., Nordestgaard B.G., Vestbo J. et al. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir. Med. 2013; 1: 543–550.

30. Zhong N., Zheng J., Wen F. et al. Efficacy and safety of budesonide / formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Curr. Med. Res. Opin. 2012; 28: 257–265.

31. Stav D., Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomised placebo-controlled study. Chest. 2009; 136: 381–386.

32. Mata M., Sarrion I., Armengot M. et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS One. 2012; 7: e48037.